4.7 Article

Evaluation of the efficacy of antifungal drugs against Paracoccidioides brasiliensis and Paracoccidioides lutzii in a Galleria mellonella model

Journal

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Volume 48, Issue 3, Pages 292-297

Publisher

ELSEVIER
DOI: 10.1016/j.ijantimicag.2016.05.012

Keywords

Alternative animal model; Antifungals; Efficacy; Paracoccidioidomycosis

Funding

  1. Conselho Nacional de Pesquisa e Desenvolvimento (CNPq)
  2. Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2015/03700-9, 2014/10446-9, 2013/10917-9]
  3. Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
  4. Programa de Apoio ao Desenvolvimento Cientifico da Faculdade de Ciencias Farmaceuticas da UNESP (PADC/FCF)
  5. Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [14/10446-9] Funding Source: FAPESP

Ask authors/readers for more resources

Paracoccidioides brasiliensis and P. lutzii belong to a group of thermodimorphic fungi and cause paracoccidioidomycosis (PCM), which is a human systemic mycosis endemic in South and Central America. Patients with this mycosis are commonly treated with amphotericin B (AmB) and azoles. The study of fungal virulence and the efficacy and toxicity of antifungal drugs has been successfully performed in a Galleria mellonella infection model. In this work, G. mellonella larvae were infected with two Paracoccidioides spp. and the efficacy and toxicity of AmB and itraconazole were evaluated in this model for the first time. AmB and itraconazole treatments were effective in increasing larval survival and reducing the fungal burden. The fungicidal and fungistatic effects of AmB and itraconazole, respectively, were observed in the model. Furthermore, these effects were independent of changes in haemocyte number. G. mellonella can serve as a rapid model for the screening of new antifungal compounds against Paracoccidioides and can contribute to a reduction in experimental animal numbers in the study of PCM. (C) 2016 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available